2023-2029 Global Rare Kidney Diseases Treatment Industry Research & Trends Analysis Report
2023-2029 Global Rare Kidney Diseases Treatment Industry Research & Trends Analysis Report
Discover the latest insights into the booming Rare Kidney Diseases Treatment Market. This report analyzes market size, growth trends (CAGR ), key players, and regional performance, offering valuable data for investors and industry professionals. Explore market drivers, restraints, and future projections for -.
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
According to the latest research analysis,the global market for Rare Kidney Diseases Treatment should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
China Rare Kidney Diseases Treatment market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
The United States Rare Kidney Diseases Treatment market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
In terms of drug class, Enzyme Replacement Therapy segment holds a share about % in 2022 and will reach % in 2029; while in terms of distribution channel, Hospital Pharmacies has a share approximately % in 2022 and will grow at a CAGR % during 2023 and 2029.
The global key manufacturers of Rare Kidney Diseases Treatment include Calliditas Therapeutics AB, GSK plc, Aurinia Pharmaceuticals, Inc., Amicus Therapeutics, Inc., Shire (Takeda Pharmaceutical Company Limited), Sanofi, Advicenne, Alexion Pharmaceuticals, Inc. and Horizon Therapeutics plc, etc. In 2022, the global top five players hold a share approximately % in terms of revenue.
This report aims to provide a comprehensive study of the global market for Rare Kidney Diseases Treatment.
Data-Driven Insights: Highlights from Our Report
(1) Global Rare Kidney Diseases Treatment market size (value), history data from 2018-2022 and forecast data from 2023 to 2029.
(2) Global Rare Kidney Diseases Treatment market competitive situation, revenue and market share, from 2018 to 2022.
(3) China Rare Kidney Diseases Treatment market competitive situation, revenue and market share, from 2018 to 2022.
(4) Global Rare Kidney Diseases Treatment segment by region (or country), key regions cover the United States, Europe, Japan, South Korea, Southeast Asia and India, etc.
(5) Global Rare Kidney Diseases Treatment segment by type and by application and regional segment by type and by application.
(6) Rare Kidney Diseases Treatment industry supply chain, upstream, midstream and downstream analysis.
Breaking Down Market Segments by Region: A Deep Dive Analysis
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Market segment by drug class, covers
Enzyme Replacement Therapy
Monoclonal Antibodies
Others
Market segment by distribution channel, can be divided into
Hospital Pharmacies
Retail Pharmacies
Online Sales
Understanding Market Segments by Key Players: Insights and Opportunities
Calliditas Therapeutics AB
GSK plc
Aurinia Pharmaceuticals, Inc.
Amicus Therapeutics, Inc.
Shire (Takeda Pharmaceutical Company Limited)
Sanofi
Advicenne
Alexion Pharmaceuticals, Inc.
Horizon Therapeutics plc
Otsuka Pharmaceutical Co., Ltd.
Reata Pharmaceuticals, Inc.
1 Market Overview
1.1 Product Overview and Scope of Rare Kidney Diseases Treatment
1.2 Global Rare Kidney Diseases Treatment Market Size and Forecast
1.3 China Rare Kidney Diseases Treatment Market Size and Forecast
1.4 China Market Percentage in Global
1.4.1 By Revenue, China Rare Kidney Diseases Treatment Share in Global Market, 2018-2029
1.4.2 Rare Kidney Diseases Treatment Market Size: China VS Global, 2018-2029
1.5 Rare Kidney Diseases Treatment Market Dynamics
1.5.1 Rare Kidney Diseases Treatment Market Drivers
1.5.2 Rare Kidney Diseases Treatment Market Restraints
1.5.3 Rare Kidney Diseases Treatment Industry Trends
1.5.4 Rare Kidney Diseases Treatment Industry Policy
2 Global Competitive Situation by Company
2.1 Global Rare Kidney Diseases Treatment Revenue by Company (2018-2023)
2.2 Global Rare Kidney Diseases Treatment Participants, Market Position (Tier 1, Tier 2 and Tier 3)
2.3 Global Rare Kidney Diseases Treatment Concentration Ratio
2.4 Global Rare Kidney Diseases Treatment Mergers & Acquisitions, Expansion Plans
2.5 Global Rare Kidney Diseases Treatment Manufacturers Product Type
3 China Competitive Situation by Company
3.1 China Rare Kidney Diseases Treatment Revenue by Company (2018-2023)
3.2 China Rare Kidney Diseases Treatment Rare Kidney Diseases Treatment Participants, Market Position (Tier 1, Tier 2 and Tier 3)
3.3 China Rare Kidney Diseases Treatment, Revenue Percentage of Local Players VS Foreign Manufacturers (2018-2023)
4 Industry Chain Analysis
4.1 Rare Kidney Diseases Treatment Industry Chain
4.2 Rare Kidney Diseases Treatment Upstream Analysis
4.3 Rare Kidney Diseases Treatment Midstream Analysis
4.4 Rare Kidney Diseases Treatment Downstream Analysis
5 Sights by Drug Class
5.1 Rare Kidney Diseases Treatment Classification
5.1.1 Enzyme Replacement Therapy
5.1.2 Monoclonal Antibodies
5.1.3 Others
5.2 By Drug Class, Global Rare Kidney Diseases Treatment Market Size & CAGR, 2018 VS 2022 VS 2029
5.3 By Drug Class, Global Rare Kidney Diseases Treatment Revenue, 2018-2029
6 Sights by Distribution Channel
6.1 Rare Kidney Diseases Treatment Segment by Distribution Channel
6.1.1 Hospital Pharmacies
6.1.2 Retail Pharmacies
6.1.3 Online Sales
6.2 By Application, Global Rare Kidney Diseases Treatment Market Size & CAGR, 2018 VS 2022 VS 2029
6.3 By Application, Global Rare Kidney Diseases Treatment Revenue, 2018-2029
7 Sales Sights by Region
7.1 By Region, Global Rare Kidney Diseases Treatment Market Size, 2018 VS 2022 VS 2029
7.2 By Region, Global Rare Kidney Diseases Treatment Market Size, 2018-2029
7.3 North America
7.3.1 North America Rare Kidney Diseases Treatment Market Size & Forecasts, 2018-2029
7.3.2 By Country, North America Rare Kidney Diseases Treatment Market Size Market Share
7.4 Europe
7.4.1 Europe Rare Kidney Diseases Treatment Market Size & Forecasts, 2018-2029
7.4.2 By Country, Europe Rare Kidney Diseases Treatment Market Size Market Share
7.5 Asia Pacific
7.5.1 Asia Pacific Rare Kidney Diseases Treatment Market Size & Forecasts, 2018-2029
7.5.2 By Country/Region, Asia Pacific Rare Kidney Diseases Treatment Market Size Market Share
7.6 South America
7.6.1 South America Rare Kidney Diseases Treatment Market Size & Forecasts, 2018-2029
7.6.2 By Country, South America Rare Kidney Diseases Treatment Market Size Market Share
7.7 Middle East & Africa
8 Sights by Country Level
8.1 By Country, Global Rare Kidney Diseases Treatment Market Size & CAGR，2018 VS 2022 VS 2029
8.2 By Country, Global Rare Kidney Diseases Treatment Market Size, 2018-2029
8.3 U.S.
8.3.1 U.S. Rare Kidney Diseases Treatment Market Size, 2018-2029
8.3.2 By Company, U.S. Rare Kidney Diseases Treatment Revenue Market Share, 2018-2023
8.3.3 By Drug Class, U.S. Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029
8.3.4 By Distribution Channel, U.S. Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029
8.4 Europe
8.4.1 Europe Rare Kidney Diseases Treatment Market Size, 2018-2029
8.4.2 By Company, Europe Rare Kidney Diseases Treatment Revenue Market Share, 2018-2023
8.4.3 By Drug Class, Europe Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029
8.4.4 By Distribution Channel, Europe Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029
8.5 China
8.5.1 China Rare Kidney Diseases Treatment Market Size, 2018-2029
8.5.2 By Company, China Rare Kidney Diseases Treatment Revenue Market Share, 2018-2023
8.5.3 By Drug Class, China Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029
8.5.4 By Distribution Channel, China Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029
8.6 Japan
8.6.1 Japan Rare Kidney Diseases Treatment Market Size, 2018-2029
8.6.2 By Company, Japan Rare Kidney Diseases Treatment Revenue Market Share, 2018-2023
8.6.3 By Drug Class, Japan Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029
8.6.4 By Distribution Channel, Japan Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029
8.7 South Korea
8.7.1 South Korea Rare Kidney Diseases Treatment Market Size, 2018-2029
8.7.2 By Company, South Korea Rare Kidney Diseases Treatment Revenue Market Share, 2018-2023
8.7.3 By Drug Class, South Korea Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029
8.7.4 By Distribution Channel, South Korea Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029
8.8 Southeast Asia
8.8.1 Southeast Asia Rare Kidney Diseases Treatment Market Size, 2018-2029
8.8.2 By Company, Southeast Asia Rare Kidney Diseases Treatment Revenue Market Share, 2018-2023
8.8.3 By Drug Class, Southeast Asia Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029
8.8.4 By Distribution Channel, Southeast Asia Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029
8.9 India
8.9.1 India Rare Kidney Diseases Treatment Market Size, 2018-2029
8.9.2 By Company, India Rare Kidney Diseases Treatment Revenue Market Share, 2018-2023
8.9.3 By Drug Class, India Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029
8.9.4 By Distribution Channel, India Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029
8.10 Middle East & Asia
8.10.1 Middle East & Asia Rare Kidney Diseases Treatment Market Size, 2018-2029
8.10.2 By Company, Middle East & Asia Rare Kidney Diseases Treatment Revenue Market Share, 2018-2023
8.10.3 By Drug Class, Middle East & Asia Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029
8.10.4 By Distribution Channel, Middle East & Asia Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029
9 Global Manufacturers Profile
9.1 Calliditas Therapeutics AB
9.1.1 Calliditas Therapeutics AB Company Information, Head Office, Market Area and Industry Position
9.1.2 Calliditas Therapeutics AB Company Profile and Main Business
9.1.3 Calliditas Therapeutics AB Rare Kidney Diseases Treatment Models, Specifications and Application
9.1.4 Calliditas Therapeutics AB Rare Kidney Diseases Treatment Revenue and Gross Margin, 2018-2023
9.1.5 Calliditas Therapeutics AB Recent Developments
9.2 GSK plc
9.2.1 GSK plc Company Information, Head Office, Market Area and Industry Position
9.2.2 GSK plc Company Profile and Main Business
9.2.3 GSK plc Rare Kidney Diseases Treatment Models, Specifications and Application
9.2.4 GSK plc Rare Kidney Diseases Treatment Revenue and Gross Margin, 2018-2023
9.2.5 GSK plc Recent Developments
9.3 Aurinia Pharmaceuticals, Inc.
9.3.1 Aurinia Pharmaceuticals, Inc. Company Information, Head Office, Market Area and Industry Position
9.3.2 Aurinia Pharmaceuticals, Inc. Company Profile and Main Business
9.3.3 Aurinia Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Models, Specifications and Application
9.3.4 Aurinia Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Revenue and Gross Margin, 2018-2023
9.3.5 Aurinia Pharmaceuticals, Inc. Recent Developments
9.4 Amicus Therapeutics, Inc.
9.4.1 Amicus Therapeutics, Inc. Company Information, Head Office, Market Area and Industry Position
9.4.2 Amicus Therapeutics, Inc. Company Profile and Main Business
9.4.3 Amicus Therapeutics, Inc. Rare Kidney Diseases Treatment Models, Specifications and Application
9.4.4 Amicus Therapeutics, Inc. Rare Kidney Diseases Treatment Revenue and Gross Margin, 2018-2023
9.4.5 Amicus Therapeutics, Inc. Recent Developments
9.5 Shire (Takeda Pharmaceutical Company Limited)
9.5.1 Shire (Takeda Pharmaceutical Company Limited) Company Information, Head Office, Market Area and Industry Position
9.5.2 Shire (Takeda Pharmaceutical Company Limited) Company Profile and Main Business
9.5.3 Shire (Takeda Pharmaceutical Company Limited) Rare Kidney Diseases Treatment Models, Specifications and Application
9.5.4 Shire (Takeda Pharmaceutical Company Limited) Rare Kidney Diseases Treatment Revenue and Gross Margin, 2018-2023
9.5.5 Shire (Takeda Pharmaceutical Company Limited) Recent Developments
9.6 Sanofi
9.6.1 Sanofi Company Information, Head Office, Market Area and Industry Position
9.6.2 Sanofi Company Profile and Main Business
9.6.3 Sanofi Rare Kidney Diseases Treatment Models, Specifications and Application
9.6.4 Sanofi Rare Kidney Diseases Treatment Revenue and Gross Margin, 2018-2023
9.6.5 Sanofi Recent Developments
9.7 Advicenne
9.7.1 Advicenne Company Information, Head Office, Market Area and Industry Position
9.7.2 Advicenne Company Profile and Main Business
9.7.3 Advicenne Rare Kidney Diseases Treatment Models, Specifications and Application
9.7.4 Advicenne Rare Kidney Diseases Treatment Revenue and Gross Margin, 2018-2023
9.7.5 Advicenne Recent Developments
9.8 Alexion Pharmaceuticals, Inc.
9.8.1 Alexion Pharmaceuticals, Inc. Company Information, Head Office, Market Area and Industry Position
9.8.2 Alexion Pharmaceuticals, Inc. Company Profile and Main Business
9.8.3 Alexion Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Models, Specifications and Application
9.8.4 Alexion Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Revenue and Gross Margin, 2018-2023
9.8.5 Alexion Pharmaceuticals, Inc. Recent Developments
9.9 Horizon Therapeutics plc
9.9.1 Horizon Therapeutics plc Company Information, Head Office, Market Area and Industry Position
9.9.2 Horizon Therapeutics plc Company Profile and Main Business
9.9.3 Horizon Therapeutics plc Rare Kidney Diseases Treatment Models, Specifications and Application
9.9.4 Horizon Therapeutics plc Rare Kidney Diseases Treatment Revenue and Gross Margin, 2018-2023
9.9.5 Horizon Therapeutics plc Recent Developments
9.10 Otsuka Pharmaceutical Co., Ltd.
9.10.1 Otsuka Pharmaceutical Co., Ltd. Company Information, Head Office, Market Area and Industry Position
9.10.2 Otsuka Pharmaceutical Co., Ltd. Company Profile and Main Business
9.10.3 Otsuka Pharmaceutical Co., Ltd. Rare Kidney Diseases Treatment Models, Specifications and Application
9.10.4 Otsuka Pharmaceutical Co., Ltd. Rare Kidney Diseases Treatment Revenue and Gross Margin, 2018-2023
9.10.5 Otsuka Pharmaceutical Co., Ltd. Recent Developments
9.11 Reata Pharmaceuticals, Inc.
9.11.1 Reata Pharmaceuticals, Inc. Company Information, Head Office, Market Area and Industry Position
9.11.2 Reata Pharmaceuticals, Inc. Company Profile and Main Business
9.11.3 Reata Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Models, Specifications and Application
9.11.4 Reata Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Revenue and Gross Margin, 2018-2023
9.11.5 Reata Pharmaceuticals, Inc. Recent Developments
10 Conclusion
11 Appendix
11.1 Research Methodology
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Market Estimation Model
11.4 Disclaimer
Research Methodology:
Rare Kidney Diseases Treatment Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|